The short version of GLP-1 analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
In 2011, the American Society of Pharmacometrics (ASoP) was founded by a number of local American groups, and over 600 members worldwide joined ASoP within 6 months. In 2012, ASoP evolved to the International Society of Pharmacometrics (ISoP) to reflect the increasing number of international members. ISoP's growth continues and the society currently represents over 1000 members from almost 30 countries around the world.
=== Effect on the human body === Stable strontium isotopes do not pose a significant health threat because the average human has an intake of about two milligrams a day. Strontium behaves very much like calcium, with a large portion of the strontium accumulating in bone. Calcium and thus strontium is recycled in the body, dissolving then reincorporating into bone. This cycle means eliminating strontium from the body may take a long time. Elimination is faster in adults whose body primarily deposits strontium on bone surfaces. In children strontium get incorporated in to hard bone minerals. The biological half-life of strontium in humans has variously been reported as from 14 to 600 days, 1,000 days, 18 years, 30 years and, at an upper limit, 49 years. The wide-ranging published biological half-life figures are explained by strontium's complex metabolism within the body. However, by averaging all excretion paths, the overall biological half-life is estimated to be about 18 years. The elimination rate of strontium is strongly affected by age and sex, due to differences in bone metabolism. The drug strontium ranelate aids bone growth, increases bone density, and lessens the incidence of vertebral, peripheral, and hip fractures. However, strontium ranelate also increases the risk of venous thromboembolism, pulmonary embolism, and serious cardiovascular disorders, including myocardial infarction. Its use is therefore now restricted.
The MRGPRX2 activation pathway in humans involves four primate-specific families of MRGPRX genes (MRGPRX1-X4) as well as the MrgprD-H families, while the MrgprA, MrgprB and MrgprC families are specific to rodents. MRGPRX2 recognizes a wide variety of basic amino acids and low-molecular-weight compounds without amino acid sequence motifs. Mast cells (MCs) also have been shown to form mast cell extracellular traps (MCETs) to entrap and kill microbes. In a multistage process, MCs become activated, the nuclear membrane disintegrates, chromatin is released into the cytoplasm, cytoplasmic granules adhere to an emerging DNA web, and the complex is released into the extracellular space. Metabolic mechanisms in IgE mediated and non-IgE mediated MC activation are not well understood. Healthy mitochondrial respiration involves maximal production of adenosine triphosphate (ATP) and minimal production of reactive oxygen species (ROS).
Clinical example: Diazepam has long been a drug of choice for status epilepticus; its high lipid solubility means it gets absorbed with equal speed whether given orally, or rectally (nonintravenous routes are convenient outside of hospital settings), but diazepam's high lipid solubility also means it does not remain in the vascular space, but soon redistributes into other body tissues. So, it may be necessary to repeat diazepam doses to maintain peak anticonvulsant effects, resulting in excess body accumulation. Lorazepam is a different case; its low lipid solubility makes it relatively slowly absorbed by any route other than intravenously, but once injected, it will not get significantly redistributed beyond the vascular space. Therefore, lorazepam's anticonvulsant effects are more durable, thus reducing the need for repeated doses. If a person is known to usually stop convulsing after only one or two diazepam doses, it may be preferable because sedative after effects will be less than if a single dose of lorazepam is given (diazepam anticonvulsant/sedative effects wear off after 15–30 minutes, but lorazepam effects last 12–24 hours). The prolonged sedation from lorazepam may, however, be an acceptable trade-off for its reliable duration of effects, particularly if the person needs to be transferred to another facility. Although lorazepam is not necessarily better than diazepam at initially terminating seizures, lorazepam is, nevertheless, replacing diazepam as the intravenous agent of choice in status epilepticus.
==== Llansó National Masonic Asylum ==== In 2023, rumors started circulating on social media that the Hogar Nacional Masónico Llansó (English: Llansó National Masonic Retirement Home), a retirement home specifically for elderly Cuban Freemasons, had 21,000 dollars of cash (unspecified "freely convertible" currency) in their treasury. After these social media posts started circulating, the Board of Trustees worried they might be robbed, because Llansó is located in a "rough part of town," in Arroyo Naranjo near La Güinera neighborhood of Havana. Grand Master Mario Urquía Carreño, who also served as the Co-President of the Board of Trustees for Llansó, volunteered that his own office safe could store the money. 19,000 of the cash was then transferred to the vaults of the Grand Lodge of Cuba at the National Masonic Temple, the rest of this money the retirement home kept for expenses and emergencies. The money transfer was signed by three Worshipful Brothers present for the transaction. The Grand Master's office was on the eleventh floor, the top floor, of the National Masonic Temple. At a Board of Trustees meeting in October 2023, Ángel Santiesteban Prats, representing the office of Grand Commander Viñas Alonso, requested a monthly count of the money be performed by Grand Treasurer Airán Cervera. Grand Master Urquía Carreño informed Santiesteban Prats that the money was in the vault of his own office, not in the possession of the Grand Treasurer.
Sources: en.wikipedia.org
=== Antibiotics === The length of antibiotic courses depends on the severity of the infection and whether bone infection is involved, but can range from 1 week to 6 weeks or more. Current recommendations are that antibiotics are only used when there is evidence of infection and continued until there is evidence that the infection has cleared, instead of evidence of ulcer healing. The choice of antibiotic depends on common local bacterial strains known to infect ulcers. Microbiological swabs are believed to be of limited value in identifying the causative strain. Microbiological investigation is of value in cases of osteomyelitis. Most ulcer infections involve multiple microorganisms. There is limited safety and efficacy data on topical antibiotics in treating diabetic foot ulcers.
Sinokrot Holding is the largest family-owned business group in Palestine, established in 1982. It is based in Ramallah, operating in 20,000 m2 of buildings with 350 employees. The company sells from more than 4,000 outlets. The chairman, Mazen Sinokrot, who was a Minister of National Economy until March 2006, as well as Chairman of the Board for the Palestine Standards Institute, Palestine Investment and Promotion Agency, and Palestine Industrial Zones and Free Zones Authority.
A cold trap is a concept in planetary science that describes an area cold enough to freeze (trap) volatiles. Cold traps can exist on the surfaces of airless bodies or in the upper layers of an adiabatic atmosphere. On airless bodies, the ices trapped inside cold traps can potentially remain there for geologic time periods, providing a glimpse into the primordial solar system. In adiabatic atmospheres, cold traps prevent volatiles (such as water) from escaping the atmosphere into space.
Several such models for mineral-mediated polymerization have emerged, such as the interlayers of layered double hydroxides like green rust over wet-dry cycles. Some scenarios for peptide formation have been proposed that are even compatible with aqueous solutions, such as the hydrophobic air-water interface and a novel "sulfide-mediated α-aminonitrile ligation" scheme, where amino acid precursors come together to form peptides. Polymerization of life's building blocks is an active area of research in prebiotic chemistry.
Neither the extent of coronary disease nor the appearance of the collateral vessels during angiography differed between the two groups, leading Kolibash to conclude that angiography is inadequate in and of itself to evaluate the functional significance of collateral vessels, and that "several physiologic variables" are most likely responsible for myocardial status in any given clinical situation. That so many adequately collateralized areas showed no evidence of subsequent improvement in myocardial perfusion also provided evidence that collaterals may often be of little or no significance. However, it is possible that such collaterals appeared too late after infarction to significantly improve overall perfusion. Since Kolibash's study, newer techniques have been used effectively to investigate the issues he raised and to characterize both the mechanism of the transformation of the native collaterals and assess their impact on myocardial perfusion and function—among them percutaneous transluminal coronary angioplasty (PTCA), ergovine-provocative spasm tests, and myocardial perfusion studies. Using PTCA, Rentrop demonstrated that collateral vessel filling jumps dramatically during coronary occlusion by balloon inflation—within ninety seconds of total occlusion. Filling improved in 15 of 16 patients; neither chest pain nor pre-inflation angina correlated with the extent of collateral filling, and coronary spasm did not occur.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.